[1] The State Council of the People's Republic of China. China issues guideline to promote the preservation and innovative development of traditional Chinese medicine(TCM) [EB/OL]. (2019-10-20)[2021-09-30]. http://english.www.gov.cn/policies/latestreleases/201910/26/content_WS5db44c20c6d0bcf8c4c15d43.html. [2] The State Council of the People's Republic of China. Notice of the general office of the China state council on the development of a number of policies and measures to accelerate the characteristics of Chinese medicine [EB/OL]. (2021-02-09)[2021-09-30].http://www.gov.cn/zhengce/content/2021-02/09/content_5586278.htm. [3] YANG ZJ, LIANG YH.Analysis of "missing items" in 1910 drug lables[J]. Nei Mongol Journal of Traditional Chinese Medicine(内蒙古中医药), 2013, 32(3): 99. [4] HU J, ZHANG H, LI B, et al.Analysis of adverse events and influencing factors in randomized controlled trials of oral Chinese medicine published in English[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2020, 45(8): 1948-1952. [5] SUN X, TAN J, TANG L, et al.Real world evidence: experience and lessons from China[J]. BMJ, 2018, 360: j5262. [6] SUN X, TAN J, TANG L, et al.Revisiting real-world study[J]. Chinese Journal of Evidence-based Medicine(中国循证医学杂志), 2017, 17(2): 126-130. [7] OYINLOLA JO, CAMPBELL J, KOUSOULIS AA.Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances[J]. BMC Health Serv Res, 2016, 16: 299. [8] WANG W, TAN J, REN Y, et al.Real-world data studies: update and future development[J]. Chinese Journal of Evidence-based Medicine(中国循证医学杂志), 2020, 20(11): 1241-1246. [9] WANG L.Opportunities and challenges in using medical big data to monitor and evaluate drug safety[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(11): 660-664. [10] SUN X, TAN J, WANG W, et al.Developing technical guidance for real-world data and studies to achieve better production and use of real-world evidence in China[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2019, 19(7): 755-762. [11] WANG W, GAO P, WU J, et al.Technical guidance for developing research databases using existing health and medical data[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2019, 19(7): 763-770. [12] TAN J, PENG X, SHU X, et al.Technical guidance for developing patient registry databases[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2019, 19(7): 771-778. [13] PENG X, SHU X, TAN J, et al.Technical guidance for designing observational studies to assess therapeutic outcomes using real-world data[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2019, 19(7): 779-786. [14] GAO P, WANG Y, LUO J, et al.Technical guidance for statistical analysis to assess therapeutic outcomes using real-world data[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2019, 19(7): 787-793. [15] WEN Z, LI L, LIU Y, et al.Technical guidance for pragmatic randomized controlled trials[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2019, 19(7): 794-802. [16] China Association of Traditional Chinese Medicine. Technical guidance for real-world studies of traditional Chinese medicine[R]. 2021. [17] SHERMAN RE, ANDERSON SA, DAL PAN GJ, et al.Real-world evidence - what is it and what can it tell us ?[J]. N Engl J Med, 2016, 375(23): 2293-2297. [18] CORRIGAN-CURAY J, SACKS L, WOODCOCK J.Real-world evidence and real-world data for evaluating drug safety and effectiveness[J]. JAMA, 2018, 320(9): 867-868. [19] National Administration of Traditional Chinese Medicine. Notice of the issuance of clinical application guidelines for Chinese medicines[EB/OL]. (2010-06-30)[2021-09-30]. http://www.satcm.gov.cn/yizhengsi/gongzuodongtai/2018-03-24/3071.html. [20] SHANG H, ZHANG B, LI Y.Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice[J]. Journal of Chinese Integrative Medicine(中西医结合学报), 2008, 6(9): 887-890. [21] National Healthcare Security Administration. Notice of the ministry of human resources and social security on the national basic medical insurance, work injury insurance and maternity insurance drug catalog (2020) [EB/OL]. (2020-12-28)[2021-09-30]. http://www.nhsa.gov.cn/art/2020/12/28/art_37_4220.html. [22] Ministry of Commerce of the People's Republic of China. Pharmaceutical distribution industry operation statistics report[R]. 2018. [23] U.S. Food & Drug Administration. Framework for FDA's realworld evidence progarm[EB/OL]. (2018-12-01)[2021-09-30]. https://www.fda.gov/media/120060/download. [24] QIAO R, LIU YQ, ZHUO L, et al.Application scope of real-world data in post-marketing drug safety monitoring and evaluation for drug safety[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(7): 620-623, 631. [25] MENG R, ZHUO L, QIAO R, et al.Application values of real-world evidence in post-marketing surveillances and evaluation for drug safety[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(7): 624-627. [26] National Medical Products Administration. NMPA issues implementation opinions to promote the inheritance, innovation and development of traditional Chinese medicine [EB/OL]. (2020-12-25)[2021-09-30].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20201225163906151.html?type=pc&m=. China issues guideline to promote the preservation and innovative development of Traditional Chinese Medicine. [27] SUN X, LI L, LIU Y, et al.Assessing clinical effects of traditional Chinese medicine interventions: moving beyond randomized controlled trials[J]. Front Pharmacol, 2021, 12: 713071. [28] SUN X, ZHANG J, WANG W, et al.Formulate technical guidance for real-world studies of traditional Chinese medicine in China to promote the transformation of clinical research of Chinese patent medicine into decision evidence[J]. Chinese Journal of Evidence-based Medicine(中国循证医学杂志), 2020, 20(9): 993-999. [29] CHENG F, XIE Y, WANG L, et al.Effect of Mailuoshutong pills on renal function indexes in the real world based on propensity scores[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(6): 537-541. [30] LI YN, LIU X, SONG Z.The combinative therapeutic effects of Mailuo Shutong Granules and synthetic medications on patients with superficial thrombophlebitis[J]. Chinese Traditional Patent Medicine(中成药), 2018, 40(6): 1266-1270. [31] LIANG G, WU C, ZHANG H, et al.Long-term toxicity of the buthus martensii karsch superfine powder[J]. China Pharmaceuticals(中国药业), 2019, 28(20): 5-8. [32] Teng G.Clinical analysis of herbal medicine causing acute renal failure in the elderly[J]. China's Naturopathy(中国民间疗法), 2015, 23(11): 71-73. |